PolyPid Ltd. reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. For FY 2025, the company reported a net loss attributable to ordinary shares of USD 8.47 million. The loss per share for the period was USD 0.41, based on a weighted average of 20,588,114 ordinary shares. In Q4 2025, PolyPid recorded an operating loss of USD 8.53 million and a net financial expense of USD 24 thousand. The company also posted a loss before income tax of USD 8.55 million for the full year. General and administrative expenses for FY 2025 amounted to USD 1.76 million, while marketing and business development expenses were USD 556 thousand. On the business front, PolyPid is in advanced discussions regarding a commercial U.S. partnership for its lead product, D-PLEX100. The company received positive FDA pre-NDA feedback supporting a rolling NDA review, with the submission expected to begin by the end of the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651023) on February 11, 2026, and is solely responsible for the information contained therein.